| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/06/2007 | US7186728 Methylene-4-azasteroids |
| 03/06/2007 | US7186727 Pyridyl-substituted spiro-hydantoin compounds and use thereof |
| 03/06/2007 | US7186726 Preferentially substituted calcium channel blockers |
| 03/06/2007 | US7186725 Anti-inflammatory compositions and methods |
| 03/06/2007 | US7186724 central nervous system disorders; psychological disorders; Parkinson's disease; Huntington's disease ; sleep disorders |
| 03/06/2007 | US7186723 Tyrosine kinase inhibitors |
| 03/06/2007 | US7186721 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines |
| 03/06/2007 | US7186720 Moderator of tumor necrosis factor; antiinflammatory agents; autoimmune diseases |
| 03/06/2007 | US7186719 Antibacterial agents |
| 03/06/2007 | US7186718 For therapy of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS |
| 03/06/2007 | US7186717 Pyrrolidine derivatives as Factor Xa inhibitors |
| 03/06/2007 | US7186716 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| 03/06/2007 | US7186715 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 03/06/2007 | US7186714 administering drugs such as 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-amine, for therapy of viral diseases caused by DNA viruses |
| 03/06/2007 | US7186713 Farnesyl dibenzodiazepinones and methods of treating cancer using same |
| 03/06/2007 | US7186711 Can be administered orally or parenterally, in small intervals until an effective dose is achieved |
| 03/06/2007 | US7186710 PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders |
| 03/06/2007 | US7186709 Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents |
| 03/06/2007 | US7186708 Steroidal compounds |
| 03/06/2007 | US7186707 Prodrugs for use as ophthalmic agents |
| 03/06/2007 | US7186706 For improving health in a woman having elevated sex hormone binding globulin levels, or who is receiving oral estrogen supplementation |
| 03/06/2007 | US7186705 silylation of O-ethyl phosphinates with hexamethyldisilazane, then introducing the 3-amino-2-hydroxypropyl moiety by reacting with epichlorohydrin and ammonia, and hydrolysis of the ethyl moiety to 3-amino-2-hydroxypropyl(benzyl or cyclohexylmethyl)phosphinic acid, used as antidepressants |
| 03/06/2007 | US7186704 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 03/06/2007 | US7186703 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 03/06/2007 | US7186702 Method of treating leishmaniasis using methyl-beta-cyclodextrin |
| 03/06/2007 | US7186701 Dehydrating agent and method for dehydrating moist article using the agent and dehydrated article obtained by the method |
| 03/06/2007 | US7186700 Administering a beta -L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug therapy of a host infected with a drug-resistant form of HBV that exhibits a mutation at the 552 codon from methionine to valine in the DNA polymerase region |
| 03/06/2007 | US7186699 Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| 03/06/2007 | US7186698 Focusing ultrasonic frequency; magnetic resonance imaging |
| 03/06/2007 | US7186697 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 03/06/2007 | US7186695 Administering organic arsenic compounds such as 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide for prophylaxis of degenarative joint disease; antiarthritic agents |
| 03/06/2007 | US7186556 Modulating transcription of genes in vascular cells |
| 03/06/2007 | US7186544 hexoses or their non-toxic salts or their intramolecular esterification products, particularly sodium gluconate, calcium gluconate or glucono delta lactone; promoting the growth of enterobacteria that short-chain fatty acids |
| 03/06/2007 | US7186503 Compounds and methods for modulating activation of NF-κB |
| 03/06/2007 | US7186421 Mineral additives for improved processing of compositions containing vitamin E and saw palmetto |
| 03/06/2007 | US7186419 Polyacrylamide hydrogel for arthritis |
| 03/06/2007 | US7186418 Composition and use of RAR antagonists for promoting chondrogenesis |
| 03/06/2007 | US7186417 Treatment of optic and otic inflammation |
| 03/06/2007 | US7186416 Foamable pharmaceutical compositions and methods for treating a disorder |
| 03/06/2007 | US7186414 Improved bioavailability; for oral and intracolonic administration |
| 03/06/2007 | US7186413 Hydrogels and water soluble polymeric carriers for drug delivery |
| 03/06/2007 | US7186407 Including claudication and critical limb ischemia, by administering fibroblast growth factor (FGF) in two doses, a single dose administered into each leg of the patient within one hour |
| 03/06/2007 | US7186405 Deodorants and anti-perspirants |
| 03/06/2007 | US7186401 comprises magnesium stearate for improved storage stability; inhalers |
| 03/06/2007 | US7186397 Cancer diagnosis; antitumor agents |
| 03/06/2007 | CA2518298A1 Biodegradable polymers, their preparation and their use for the manufacture of bandages |
| 03/06/2007 | CA2389264C Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 03/06/2007 | CA2384525C Thienylhydrazon with digitalis-like properties (positive inotropic effects) |
| 03/06/2007 | CA2382405C New processes for synthesizing (3as)-5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine |
| 03/06/2007 | CA2355313C Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 03/06/2007 | CA2312493C Novel suppository form comprising an acid-labile active compound |
| 03/06/2007 | CA2308806C Flavone analogues useful as antirejection agents |
| 03/06/2007 | CA2302641C Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation |
| 03/06/2007 | CA2294990C Pharmaceutical compositions and methods for effecting dopamine release |
| 03/06/2007 | CA2292895C Cyanoguanidines as cell proliferation inhibitors |
| 03/06/2007 | CA2286315C 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor |
| 03/06/2007 | CA2277913C New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 03/06/2007 | CA2268626C Pharmaceutical composition for rapid suspension in aqueous media |
| 03/06/2007 | CA2263961C Cocaine receptor binding ligands |
| 03/06/2007 | CA2252110C 5-androstene 3.beta.,17.alpha. diol as an inhibitor of tumor growth |
| 03/06/2007 | CA2219132C Nucleosides with anti-hepatitis b virus activity |
| 03/06/2007 | CA2211313C Synergistic personal hygiene process comprising the steps of combining a cosmetic cleansing composition with an application vehicle |
| 03/06/2007 | CA2202228C Novel retinoids |
| 03/06/2007 | CA2200986C Medicaments |
| 03/06/2007 | CA2191677C Cerebral function improving agents |
| 03/06/2007 | CA2189131C Use of pteridine derivatives as no-synthase inhibitors |
| 03/06/2007 | CA2186243C Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity |
| 03/06/2007 | CA2168319C 4-mercaptobenzoylguanidine derivatives |
| 03/06/2007 | CA2167694C Catharanthus roseus binary alkaloid antimitotic derivatives |
| 03/06/2007 | CA2163935C 17-(3-imino-2-alkypropenyl)-5.beta., 14.beta.-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same |
| 03/06/2007 | CA2129159C Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 03/06/2007 | CA2128142C Pharmaceutical combination containing ras inhibitor and endothelin antagonist for the treatment of cardiovascular disorders |
| 03/02/2007 | CA2554859A1 A process for preparing an injectable sterile pharmaceutical formulation containing at least piperacillin sodium and tazobactam sodium active principles |
| 03/01/2007 | WO2007025303A2 Non-steroidal antiandrogens |
| 03/01/2007 | WO2007025284A1 Triazole compounds and methods of making and using the same |
| 03/01/2007 | WO2007025269A2 Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
| 03/01/2007 | WO2007025261A2 Non-irritating solvent-borne polymeric coatings for application to the skin |
| 03/01/2007 | WO2007025247A2 Transglutaminase inhibitors and methods of use thereof |
| 03/01/2007 | WO2007025213A2 Use of sodium channel blockers for the management of musculoskeletal pain |
| 03/01/2007 | WO2007025212A2 Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
| 03/01/2007 | WO2007025186A2 Hydrazone agents to treat cutaneous lesions |
| 03/01/2007 | WO2007025178A2 Rolyvalent multimeric compositions containing active polypeptides, pharmaceutical compositions and methods of using the same |
| 03/01/2007 | WO2007025177A2 Neurogenesis by muscarinic receptor modulation |
| 03/01/2007 | WO2007025169A2 Hif inhibitors |
| 03/01/2007 | WO2007025146A2 Balsalazide formulations and manufacture and use thereof |
| 03/01/2007 | WO2007025144A1 5-ht2c receptor agonists as anorectic agents |
| 03/01/2007 | WO2007025103A2 Organic compounds for treating reduced dopamine receptor signalling activity |
| 03/01/2007 | WO2007025098A2 Triazole compounds and methods of making and using the same |
| 03/01/2007 | WO2007025094A2 Stabilized and preserved ketotifen ophthalmic compositions |
| 03/01/2007 | WO2007025092A2 Stabilized and preserved ketotifen ophthalmic compositions |
| 03/01/2007 | WO2007025089A2 Triazole compounds and methods of making and using the same |
| 03/01/2007 | WO2007025069A2 Diazaspirodecane orexin receptor antagonists |
| 03/01/2007 | WO2007025064A2 METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES |
| 03/01/2007 | WO2007025055A2 Benztropine compounds and uses thereof as dopamine uptake inhibitors |
| 03/01/2007 | WO2007025009A2 Indenoisoquinolinone analogs and methods of use thereof |
| 03/01/2007 | WO2007024993A2 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 03/01/2007 | WO2007024982A2 Methods for managing adipocyte fat accumulation |
| 03/01/2007 | WO2007024971A2 Hedgehog pathway antagonists to treat disease |
| 03/01/2007 | WO2007024954A1 Chemical compounds |
| 03/01/2007 | WO2007024945A1 Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |